Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. Its product portfolio comprises Cumulase, which is used for in vitro fertilization; Hylenex, a human recombinant formulation of recombinant human PH20 that is used as an agent for drug and fluid infusion; Chemophase, a Phase I/IIa clinical trial product used as a chemoadjuvant for superficial bladder cancer; Enhanze Technology, a Phase I clinical trail product used as an agent for enhanced drug delivery; and HTI-101, a pre-clinical stage product for the treatment of inflammation and oncology. The company was founded in 1998 and is based in San Diego, California.